|
US5997864A
(en)
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
|
US20040087498A1
(en)
*
|
1991-02-28 |
2004-05-06 |
Novo Nordisk Health Care Ag |
Modified factor VII
|
|
WO1999003498A1
(en)
*
|
1997-07-18 |
1999-01-28 |
Novo Nordisk A/S |
USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
|
|
US7247708B2
(en)
*
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6747003B1
(en)
*
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6693075B1
(en)
*
|
1997-10-23 |
2004-02-17 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6406488B1
(en)
|
1998-08-27 |
2002-06-18 |
Heartstent Corporation |
Healing transmyocardial implant
|
|
EP0987274A1
(en)
|
1998-09-15 |
2000-03-22 |
Hoechst Marion Roussel Deutschland GmbH |
Factor VIIa Inhibitors
|
|
EP1059302A1
(en)
|
1999-06-08 |
2000-12-13 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitors
|
|
US6924359B1
(en)
*
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
|
EP1095933A1
(en)
|
1999-10-30 |
2001-05-02 |
Aventis Pharma Deutschland GmbH |
Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
|
|
NZ521257A
(en)
*
|
2000-02-11 |
2004-10-29 |
Maxygen Aps |
Factor VII or VIIa-like molecules
|
|
WO2001079444A2
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc |
Albumin fusion proteins
|
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
EP1162194A1
(en)
|
2000-06-06 |
2001-12-12 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
|
|
AU2001269803A1
(en)
*
|
2000-06-20 |
2002-01-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for modulating muscle cell and tissue contractility
|
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
|
US7160540B2
(en)
*
|
2000-06-30 |
2007-01-09 |
Regents Of The University Of Minnesota |
Methods for detecting activity of clottings factors
|
|
US6423826B1
(en)
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
|
NZ526269A
(en)
|
2000-12-06 |
2004-11-26 |
Aventis Pharma Gmbh |
Guanidine and amidine derivatives as factor Xa inhibitors having antithrombotic effect
|
|
US6825323B2
(en)
*
|
2001-01-10 |
2004-11-30 |
The United States Of America As Represented By The Secretary Of The Army |
Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
|
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
|
AU2002249096B2
(en)
*
|
2001-03-22 |
2007-06-28 |
Novo Nordisk Health Care Ag |
Coagulation factor VII derivatives
|
|
HUP0304050A3
(en)
*
|
2001-05-02 |
2005-12-28 |
Novo Nordisk As |
Modified fvii in treatment of ards
|
|
EP1270551A1
(en)
|
2001-06-26 |
2003-01-02 |
Aventis Pharma Deutschland GmbH |
Urea derivatives with antiproteolytic activity
|
|
AU2002326135A1
(en)
*
|
2001-09-10 |
2003-03-24 |
Florence Medical Ltd. |
Individual ffr determination for lesions of a multi-lesioned blood vessel
|
|
EP2305311A3
(en)
|
2001-10-10 |
2011-07-20 |
BioGeneriX AG |
Glycoconjugation of peptides
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
AU2002336920A1
(en)
*
|
2001-11-02 |
2003-05-12 |
Novo Nordisk Health Care Ag |
Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
|
|
EP1314733A1
(en)
|
2001-11-22 |
2003-05-28 |
Aventis Pharma Deutschland GmbH |
Indole-2-carboxamides as factor Xa inhibitors
|
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
|
BR0215216A
(pt)
|
2001-12-21 |
2004-11-16 |
Novo Nordisk Healthcare Ag |
Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
|
|
CN1606452A
(zh)
*
|
2001-12-21 |
2005-04-13 |
诺沃娜第克公司 |
修饰的因子ⅶ多肽的液体组合物
|
|
WO2003093465A1
(en)
*
|
2002-04-30 |
2003-11-13 |
Maxygen Holdings Ltd. |
FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
|
|
ES2377959T3
(es)
*
|
2002-05-03 |
2012-04-03 |
Novo Nordisk Health Care Ag |
Composiciones sólidas estabilizadas de factor VII modificado
|
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
|
KR20050013148A
(ko)
*
|
2002-06-21 |
2005-02-02 |
노보 노르디스크 에이/에스 |
인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
|
|
EP1549677B1
(en)
*
|
2002-09-30 |
2011-04-13 |
Bayer HealthCare LLC |
FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
|
|
US7358268B2
(en)
|
2002-12-04 |
2008-04-15 |
Sanofi-Aventis Deutschland Gmbh |
Imidazole derivatives as factor Xa inhibitors
|
|
US7429581B2
(en)
|
2002-12-23 |
2008-09-30 |
Sanofi-Aventis Deutschland Gmbh |
Pyrazole-derivatives as factor Xa inhibitors
|
|
US20040176704A1
(en)
*
|
2003-03-04 |
2004-09-09 |
Stevens Timothy A |
Collection device adapted to accept cartridge for point of care system
|
|
CA2518327A1
(en)
*
|
2003-03-18 |
2004-09-30 |
Novo Nordisk Health Care Ag |
Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
|
|
DK1608745T3
(da)
*
|
2003-03-20 |
2009-06-15 |
Bayer Healthcare Llc |
FVII eller FVIIa-Varianter
|
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
SG155777A1
(en)
|
2003-04-09 |
2009-10-29 |
Neose Technologies Inc |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US20040202726A1
(en)
*
|
2003-04-10 |
2004-10-14 |
Deshay Samuel L. |
Topical blood pressure composition
|
|
EP1479677A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
|
EP1479675A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Indazole-derivatives as factor Xa inhibitors
|
|
US7317027B2
(en)
|
2003-05-19 |
2008-01-08 |
Sanofi-Aventis Deutschland Gmbh |
Azaindole-derivatives as factor Xa inhibitors
|
|
US7223780B2
(en)
|
2003-05-19 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
|
|
EP1479680A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Azaindole derivatives as Factor Xa inhibitors
|
|
US7741341B2
(en)
|
2003-05-19 |
2010-06-22 |
Sanofi-Aventis Deutschland Gmbh |
Benzimidazole-derivatives as factor Xa inhibitors
|
|
CN1780638B
(zh)
*
|
2003-05-23 |
2010-04-14 |
诺和诺德医疗保健公司 |
氧化硅涂层玻璃作为容器内壁材料的用途及以该材料作内壁的容器
|
|
US7029675B1
(en)
*
|
2003-06-04 |
2006-04-18 |
Shu-Wha Lin |
Hepsin antagonist and methods of use
|
|
DK1644504T3
(da)
*
|
2003-06-19 |
2010-05-25 |
Bayer Healthcare Llc |
Faktor VII- eller -VIIA-Gla-domænevarianter
|
|
WO2004112828A1
(en)
|
2003-06-25 |
2004-12-29 |
Novo Nordisk Health Care Ag |
Liquid composition of factor vii polypeptides
|
|
JP5306597B2
(ja)
*
|
2003-07-01 |
2013-10-02 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
|
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
|
JP5653572B2
(ja)
|
2003-08-14 |
2015-01-14 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
ATE507822T1
(de)
*
|
2003-12-19 |
2011-05-15 |
Novo Nordisk Healthcare Ag |
Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
|
|
EP1568698A1
(en)
|
2004-02-27 |
2005-08-31 |
Aventis Pharma Deutschland GmbH |
Pyrrole-derivatives as factor Xa inhibitors
|
|
JP2008514677A
(ja)
*
|
2004-09-29 |
2008-05-08 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
陰イオン交換物質からの分画溶出によるｖｉｉ因子ポリペプチドのバルクの精製
|
|
WO2006050247A2
(en)
|
2004-10-29 |
2006-05-11 |
Neose Technologies, Inc. |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
WO2006074467A2
(en)
|
2005-01-10 |
2006-07-13 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
WO2008011633A2
(en)
|
2006-07-21 |
2008-01-24 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
|
KR20100016160A
(ko)
|
2007-04-03 |
2010-02-12 |
바이오제너릭스 에이지 |
글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
|
|
MX2009013259A
(es)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Proceso mejorado para la produccion de azucares de nucleotidos.
|
|
CN101965200B
(zh)
|
2008-02-27 |
2013-06-19 |
诺沃-诺迪斯克有限公司 |
缀合的因子ⅷ分子
|
|
NZ593815A
(en)
|
2008-12-19 |
2013-05-31 |
|
Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
|
|
WO2011028228A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
NZ623576A
(en)
|
2010-03-19 |
2015-11-27 |
Baxter Healthcare Sa |
Tfpi inhibitors and methods of use
|
|
KR101294351B1
(ko)
*
|
2010-05-27 |
2013-08-07 |
동국대학교 산학협력단 |
뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법
|
|
CA2864126A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
ES2935489T3
(es)
|
2012-02-15 |
2023-03-07 |
Bioverativ Therapeutics Inc |
Composiciones de factor VIII y métodos de preparación y uso de las mismas
|
|
WO2013141965A1
(en)
|
2012-03-21 |
2013-09-26 |
Baxter International Inc. |
Tfpi inhibitors and methods of use
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
EP3324960A4
(en)
*
|
2015-07-22 |
2019-01-23 |
Iconic Therapeutics, Inc. |
METHOD FOR TREATING DISORDER IN CONNECTION WITH ANGIOGENESIS AND NEOVASCULARIZATION
|
|
MX2018001497A
(es)
|
2015-08-03 |
2018-05-15 |
Bioverativ Therapeutics Inc |
Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
|
|
EP3402537B1
(en)
|
2016-01-15 |
2021-01-06 |
Rigshospitalet |
Quantitative pet imaging of tissue factor expression using 18f-labelled active site inhibited factor vii
|
|
US20190358351A1
(en)
|
2016-11-17 |
2019-11-28 |
Minerva Imaging Aps |
177-lu labeled active site inhibited factor vii
|
|
IL319473A
(en)
|
2016-12-02 |
2025-05-01 |
Bioverativ Therapeutics Inc |
Methods for treating hemophilic arthritis using chimeric blood clotting factors
|
|
DK3793588T3
(da)
|
2018-05-18 |
2025-06-16 |
Bioverativ Therapeutics Inc |
Fremgangsmåder til behandling af hæmofili a
|